Sponsor pipeline

Hebei Medical University Fourth Hospital clinical trial pipeline

Get alerts when Hebei Medical University Fourth Hospital's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-05 NCT07857226 Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer Phase 2 Not Yet Recruiting

Active trials by phase

Phase 1
3
Phase 2
33
Phase 2/3
2
Phase 4
4
Not charted: 10 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 13

Breast Cancer (15) · Esophageal Cancer (13) · Colorectal Cancer (6) · Lung Cancer (5) · HER2-Positive Cancer (4) · Non-Small Cell Lung Cancer (NSCLC) (3) · Liver Cancer (2) · Small Cell Lung Cancer (2) · Triple-Negative Breast Cancer (2) · Heart Disease (1)

Get alerts when Hebei Medical University Fourth Hospital's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free